Directory:Symphony Medical

MyWikiBiz, Author Your Legacy — Saturday November 27, 2021
Revision as of 00:51, 5 January 2007 by OmniMediaGroup (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigationJump to search

<adsense> google_ad_client = "pub-5512298628457000"; google_ad_width = 728; google_ad_height = 15; google_ad_format = "728x15_0ads_al"; google_ad_channel = ""; google_color_border = "FFFFFF"; google_color_bg = "FFFFFF"; google_color_link = "0066CC"; google_color_text = "000000"; google_color_url = "008000"; </adsense>


Symphony Medical Inc.
Type [[Company_Type:=Private|Private]]
Founded [[Year_Started:=2002|2002]]
Headquarters Template:Country data US [[City:=Laguna Hills|Laguna Hills]], [[State_Name:=California|California]], [[Country_Name:=United States|USA]]
Industry[[NAICS_Code1_Title:=Research and Development In The Physical, Engineering, and Life Sciences|Research and Development In The Physical, Engineering, and Life Sciences]]
Contact 26051 Merit Cir Ste 104
Laguna Hills, CA  US  92653-7008
949.348.1188  
[http://www.symphonymed.com/ www.symphonymed.com]   
Reference NAICS:54171

Symphony Medical, based in Laguna Hills, CA is a venture-backed development stage company formed in 2002 to address the unmet clinical needs of millions of patients suffering from cardiac conduction disorders.

During the last 3 years, the Company has successfully invented safe, cost-effective biologic products that utilize proprietary biopolymers to treat patients with rhythm disturbances through non-destructive (non-ablative) means. Biologic material is injected directly into specific locations of the heart during open chest surgery or via a minimally invasive procedure employing a catheter-based cardiac delivery device.

The Company’s expertise and technology was developed through collaboration with world-class physicians and researchers from The Cleveland Clinic, Mayo Clinic Rochester and University of California, San Francisco. Symphony matched practicing electrophysiologists expert in cardiac arrhythmias with academic researchers and scientists working with biopolymers, cell therapies and biologics in order to develop proprietary biotherapeutic and tissue engineering tools to effectively treat conduction abnormalities such as post-operative atrial fibrillation, chronic atrial fibrillation, and left ventricular tachycardia.

Our initial product is aimed to prevent post-operative atrial fibrillation (POAF), a condition which is a common side effect of open heart surgery and affects about one-third of all patients undergoing cardiac surgery. To date, POAF remains an unresolved medical condition. Patients must remain in a specialized post-surgical unit for a number of additional days while physicians attempt to manage POAF with an aggressive medication regiment. The combination of employing these medications along with prolonged stays in the post-surgical ICU or CCU creates a significant non-recoverable expense to hospitals.

The Company's POAF treatment kit contains proprietary fibrin sealant, a practical device to identify the correct injection spots on the heart and a unique applicator. At the end of the open chest heart surgery, the cardiac surgeon injects the fibrin sealant into certain strategic conduction areas of the heart referred to as 'fat pads'. The entire procedure can be accomplished in less than 3 minutes.

Based on the Company's preclinical and Phase I clinical trial results, we anticipate this simple non-destructive procedure will be used as a prophylactic treatment to prevent patients from developing post-operative atrial fibrillation. For more information about our clinical trial, click here.

The Company's second product under development is a catheter-delivered biotherapeutic designed to regulate ventricular rate in atrial fibrillation (AF) patients. The first generation of this product, utilizing a patient's own (autologous) fibroblast cells, has undergone proof of concept in large animal models. For more information about this preclinical study, click here. Initial clinical trials are anticipated to begin in 2007.

In addition to our atrial fibrillation therapies, Symphony Medical also has a pipeline of proprietary technologies aimed at ventricular reconstruction based on the combination of biopolymers and devices.


<adsense> google_ad_client = "pub-5512298628457000"; google_ad_width = 728; google_ad_height = 90; google_ad_format = "728x90_as"; google_ad_type = "text_image"; google_ad_channel = ""; google_color_border = "FFFFFF"; google_color_bg = "FFFFFF"; google_color_link = "0066CC"; google_color_text = "000000"; google_color_url = "008000"; </adsense>